Cereno Scientific Ab

Niklas Bergh

Sverker Jern

Jonas Faijerson Saljo

Nils Ove Gustafsson

Hans Roger Marcus Martensson

Jonas Faijerson Saijo

Jonas Faijerson SÄLJÖ

Pia Larsson

Hans Roger Marcus MÅRTENSSON

There is herein provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.

Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

There is provided herein a pharmaceutical formulation having one or more component comprising valproic acid (VPA) and/or a pharmaceutically acceptable salt thereof; and one or more secondary acid, and optionally comprising one or more pharmaceutically acceptable excipient. There is also provided uses of such formulations.

Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof

There is herein provided valproic acid, or a pharmaceutically acceptable salt, thereof, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with valproic acid, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.

Growing community of inventors

Askim, Sweden

Niklas Bergh